Lufax Holding Ltd vs Zoetis Inc — how do they compare? Lufax Holding Ltd trades at $1.56 (market cap $2.41B), while Zoetis Inc trades at $75.11 (market cap $30.92B). The key difference: Zoetis Inc is far larger — about 12.8× Lufax Holding Ltd's market cap, and Zoetis Inc pays a 2.83% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| LU | ZTS | |
|---|---|---|
Market Cap | $2.41B | $30.92B |
Sector | Technology | Health |
52-Week High | $4.40 | $156.76 |
52-Week Low | $1.23 | $71.91 |
Enterprise Value | — | $38.49B |
Dividend Yield | — | 2.83% |
Signals from Pluang's Aura AI — not financial advice
LU trades at $1.50, up 0.67% on the day, with a neutral technical signal and bearish moving averages. The stock shows deep value on price-to-sales (0.42) and price-to-book (0.12) ratios but faces profitability challenges with a -9.08% net margin and negative ROE. Recent earnings misses and a securities class action lawsuit filed in May 2026 create headwinds, though analyst consensus remains 69% buy-rated.
The outlook is cautious due to litigation overhangs and persistent losses, but low valuations may attract value investors if operational improvements materialize. Key risks include legal liabilities and execution on turning profitability; upside depends on management's ability to stabilize earnings amid competitive pressures in Chinese financial services.
No Aura AI signal available yet.
Trailing returns across standard periods
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →